• Home | Global Data CRO
  • Our Company
    • About Us
    • Executive Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Leaders
    • Working with MMS
    • Certifications
  • Services
    • Regulatory Affairs
      • Regulatory Affairs Services
      • Regulatory Strategy Consulting
      • Regulatory Affairs Management
      • Regulatory Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Transparency Services
      • Transparency and Disclosure Services
      • REGISTRATION AND RESULTS DISCLOSURES
      • DATA AND DOCUMENT ANONYMIZATION
      • LAY SUMMARIES
    • Quality and Compliance services
    • Drug Safety and Pharmacovigilance
    • Rare Disease
    • Quality Control Services
    • Project Advisory Services
    • Data Science
  • Technology
    • Datacise
    • Automatiqc
    • PVantage
    • Technology Implementation
    • SmartStart Document Templates
  • Functional Services (FSP)
  • Webinars
  • News and Media
  • MMS Blog
  • Careers
    • MMS Careers
    • Opportunities
    • MMS Experience
    • MMS Culture
    • Global Benefits
    • FAQ
  • Learning
  • Contact Us
MMS Holdings
Aligning a Global Team, Engaging Colleagues, and the Importance of a Human Connection: A Conversation with Daria Fellrath

Aligning a Global Team, Engaging Colleagues, and the Importance of a Human Connection: A Conversation with Daria Fellrath

by Avery Zimmerman | Jan 16, 2023 | Blog

In this blog, we sat down with Daria Fellrath, Senior Manager of Global Talent and Culture Management at MMS, to discuss how important it is to align a global team, engage with colleagues, and foster human connections across organizations. Daria’s leadership and...

Recent Posts

  • What You Need to Know About Phase 1 Clinical Trial Designs and Bioequivalence (BE)/Bioavailability (BA) in the US and EU
  • Clinical Data Managers Should Do These Three Things for Any Post-Production Changes
  • FDA and the Real-World: Key Changes from Draft to Final Guidance on RWD and RWE
  • Relaunch of EMA Policy 0070 in September 2023: The European Medicines Agency’s Revived Commitment to Transparency
  • “D” is for Discipline: Everything You Need to Know About FDA’s Type D Meetings

Tags

biostatistics Careers clinical research clinical study reports clinical trial disclosure clinical trials clinical trial transparency Compliance conference COVID-19 CRO data management data privacy data science decentralized clinical trials diversity and inclusion drug development eCOA & ePro EMA FDA Functional Service Provider (FSP) GXP auditing Health Analytics Collective innovation Lay summaries leadership medical writing MMS Academy NDA submission News Orphan Drug Designation Applications PDUFA VII pharmacovigilance PhUSE plain language summary Policy 0070 Praxis bioresearch quality and compliance quality control rare disease real world data regulatory affairs regulatory operations statistical programming transparency